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ABSTRACT
This proposal aimed at defining the use of glycopeptides containing tumor associated carbohydrate antigens (TACA) , that bind multiple MHC class I alleles, as potential preventive vaccines for carcinomas on a large scale. Our recent results (JEM 2004; 199:707, see appendix) suggest that CD8+ T cells (CTL) are capable of recognizing TACA in a conventional class I MHC-restricted fashion. TF, a disaccharide, and Tn, its immediate precursor, are TACA largely expressed in carcinomas. TF and Tn can be successfully used as T helper (Th)-independent vaccines when conjugated to designer peptide with optimal binding affinity for class I MHC molecules. TF-and Tn-specific CTL generated with this strategy are capable of recognizing TACA-expressing tumors in vitro, suggesting that glycopeptides are as effectively presented by class I MHC molecules as non-glycosylated peptides (JEM 2004; 199:707) . Because the exact sequences of endogenously synthesized glycopeptides are unknown, the TACA-specific T cell repertoire elicited by carbohydrate-based vaccines is assumed to be degenerate. Here we report that mice genetically manipulated to develop TACA-expressing mammary tumors are not tolerant to glycopeptide vaccination ( Figures 1 and 2 Tumor associated carbohydrate antigens (TACA) are a group of tumor antigens identified and characterized by their reaction with antibodies and lectins.
TACA are expressed in the embryo, but not in differentiated cells in adult tissues. In tumor cells, TACA are generated early during tumor progression due to aberrant glycosylation. Because several neoplastic tissues express the same TACA, this approach is very interesting because avoids the need for epitope mapping, a major limitation in cancer immunotherapy.
Moreover, our idea to design TACA-containing glycopeptides with the capacity to bind multiple HLA alleles (the large majority of the A2 subtypes have been studied with the resources provided by this grant) has the potential to indicate a new avenue for low costs cancer prevention in a large scale, and in a broad range of tumors.
Two interesting TACA for CTL-based immunotherapy are the Thomsen-Freidenreich (TF) antigen (α-Gal-(1->3)-β-GalNAc-O-Ser) and its precursor Tn (GalNAc-O-Ser).
In vivo studies in mice indicated that it is possible to generate anti-TF and anti-Tnspecific CTL (The Journal of Experimental Medicine, 2004. 199 :707, Figure 1 ). TACAspecific CTL generated with this antigenic strategy are capable of killing a variety of TACA-expressing tumors in vitro (The Journal of Experimental Medicine, 2004. 199 :707, Figure 5 ).
TACA-specific T cell receptors (TcRs) recognize the amino acid linker together with the TACA (The Journal of Experimental Medicine, 2004. 199 :707, Figure 6 ). The recognition of the amino acid linker by TACA-specific TcR is of the most importance for therapeutic design. In fact, longer amino acid linkers, as lysine or ornitine, although had potentials to better present the TACA antigen to T cells by "bulging" from the HLA binding groove, do not generate TACA-specific CTL, but a strong peptidespecific response (The Journal of Experimental Medicine, 2004. 199 :707, Figure 3 ).
The TACA-specific T cell clonal repertoire is very cross-reactive, a great advantage in immunotherapy because the sequences of the endogenous peptides presenting TACA to T cells are unknown (The Journal of Experimental Medicine, 2004. 199 :707, Figure 6 ).
Tn was found a better TACA vaccine candidate than TF in these studies (The Journal of Experimental Medicine, 2004. 199 :707, Figure 1 ). In fact, within the TF molecule, Tn is the carbohydrate molecule recognized by the large majority of TcRs (The Journal of Experimental Medicine, 2004. 199 :707, Figure 2 ). This concept is very relevant to immunotherapy because underlines the possible recognition of Tn by TF-specific CTL and viceversa. Tn is more immunogenic than TF probably because of its small size that suggests a greater, and more stable antigen presentation to TcRs.
To validate this vaccine approach, we demonstrated that the TACA-containing glycopeptides breake immunological tolerance in tumor-bearing mice (namely MUC1/MT transgenic) that express TF and Tn molecules in the context of the MUC1 glycoprotein (Immunology and Cell Biology, 2005. 83 :440, Figure 1 ). These preliminary experiments, although not described in the SOW, were required before breeding the double transgenic lineage with the A2/K b transgenic mice to generate a triple transgenic, "humanized" spontaneous tumor model (MUC1/MT/A2K b ). Breaking immunological tolerance is very important as a proof of principle for the use of this approach in a clinical setting. Accordingly, TACA-specific T cell clones derived from MUC1/MT transgenic mice recognize Tn-expressing tumors in vitro, further supporting that immunological tolerance has been successfully broken (Immunology and Cell Biology, 2005 . 83:440, Figure 2 ).
The generation of TACA-specific CTL responses in healthy normal donors has been determined by in vitro priming, by using as immunogens the glycopeptide sequences earlier proposed and in vitro cultured dendritic cells (DC) as antigen presenting cells. Glycopeptides have been found capable of binding class I MHC molecules with a higher affinity than corresponding natural peptide sequences (Immunology and Cell Biology, 2005 . 83:440, Table 1 ). These results confirm the observation in the murine K b allele model (The Journal of Experimental Medicine, 2004. 199:707, Table 1 ). The demonstration that TACA conjugation does not affect MHC binding is very relevant in support of this vaccination strategy. In terms of immunogenicity, Tn-containing glycopeptides have been proven capable of inducing a high CTL activation following a single stimulation in vitro in healthy human donors (Immunology and Cell Biology, 2005. 83:440, Table 2 ).
The breeding of the triple transgenic lineage (MUC1/MT/A2K b ) has been successful. All the glycopeptides tested, including the designer Tn-containing glycopeptides, were immunogenic in these mice. However, we were not satisfied on the degree of carbohydrate specificity of the T cell repertoire generated in the triple transgenic lineage, often capable to recognize the peptide backbone used for carbohydrate conjugation with high avidity and affinity. Unfortunately, although the MUC1/MT mouse model is ideal to study immunotherapy in vivo, the "humanized" triple transgenic lineage (MUC1/MT/A2/K b ) is not suitable to test the efficacy of A2-restricted TACA-containing glycopeptides in treating mammary tumors. We believe that the double expression of both, human and murine MHC molecules (A2/Kb) in some instances selects a T cell repertoire profoundly different from A2 human donors.
Because of the success of the anti-tumor responses generated in humans, we decided to expand the clonal repertoire and to transfer T cell clones in vivo in the triple transgenic lineage as passive immunotherapy.
We generated a variety of TACA-specific T cell clones to define the most cross-reactive and select those with the best growing rate in vitro (T cell transfer requires a large number of functional T cells). In support of this vaccine approach we found a large number of TACA-specific T clones capable of recognizing a variety of human A2 tumors in vitro.
The studies of T cell transfer are still in progress.
Key Research Accomplishments 1. TACA conjugation does not affect the MHC class I binding affinity of designer, or natural peptide sequences (The Journal of Experimental Medicine, 2004. 199:707, 
